GLP-1 drugs such as semaglutide and tirzepatide have the best evidence for women’s weight loss, and they work across menopause stages. Two bone drugs and one libido drug also have trials in women. Most other peptides pitched to women, including collagen, GHK-Cu, tesamorelin and sermorelin, don’t have the evidence the pitch claims. Below: what has …
Most of the evidence behind the energy claims on peptides comes from mice, cell studies and company press releases. So here is what each compound actually has. No controlled human trial cited on this page shows a peptide raising energy. Some have hormone-level data. One has an FDA approval for a rare disease. The rest …
In gold peptide skincare, a few of the peptides have human trials. The gold has the shine. I read the current ingredient labels of the five products on this page on October 18, 2026. In four of them, gold sits tenth or lower on the list. In the fifth, the gold is listed as a …
Research use only. Nothing on this page is medical advice. Thymulin isn’t approved for human use. Thymulin is a nine-amino-acid hormone made by the thymus, and it only works when it carries one zinc ion. In mice it calms inflammation, and a 2026 Nature Communications study found it restored antitumor T-cell responses in aged mice. …
No published or registered trial has tested CJC-1295 and ipamorelin together in people. The numbers quoted for the pair come from CJC-1295 alone, and the one ipamorelin trial with published efficacy results didn’t beat placebo. This page covers what each peptide has been tested on and what the stacking idea rests on. It also covers …
NAD+ is a coenzyme, not a peptide, so “NAD peptide” is a misnomer. Supplements made of its precursors, NR and NMN, reliably raise NAD+ in the blood. Whether that improves health is a different question, and human trials so far show inconsistent or no benefit. No outcome trial has tested NAD+ injections or IV drips …